Literature DB >> 19630717

Potential role of ADAMTS13 in the progression of alcoholic hepatitis.

Masahito Uemura1, Yoshihiro Fujimura, Tomomi Matsuyama, Masanori Matsumoto, Masatoshi Ishikawa, Hiromichi Ishizashi, Seiji Kato, Tatsuhiro Tsujimoto, Masao Fujimoto, Hitoshi Yoshiji, Chie Morioka, Hiroshi Fukui.   

Abstract

Alcoholic hepatitis (AH) is a potentially life-threatening complication of alcohol abuse. The severe form of AH, severe alcoholic hepatitis (SAH), is characterized by multiorgan failure (MOF) with manifestations of acute hepatic failure and is associated with high morbidity and mortality. However, the pathogenesis of SAH in addition to AH remains to be elucidated. Recent advances showed that ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13) is closely related to thrombotic thrombocytopenic purpura, a multiorgan disorder. Decreased activity of plasma ADAMTS13 (ADAMTS13:AC) leads to the accumulation of unusually large von Willebrand factor multimers (UL-VWFM) and subsequent platelet clumping and/or thrombi under high shear stress, resulting in microcirculatory disturbances. Immunological studies and in situ hybridization have indicated that ADAMTS13 is produced exclusively in hepatic stellate cells (HSCs). Plasma ADAMTS13:AC was extremely low in fatal SAH cases, and enhanced UL-VWFM production with deficient ADAMTS13:AC may contribute to the progression of MOF through microcirculatory disturbances in SAH and AH. Considering that ADAMTS13 is synthesized in HSCs and its substrate, UL-VWFM, is produced in transformed vascular endothelial cells, the imbalance between ADAMTS13:AC and VWF:Ag in AH patients might also involve sinusoidal microcirculatory disturbances and subsequent liver injury. It will be necessary to clarify the mechanism of the decrease in plasma ADAMTS13:AC in association with pro-inflammatory cytokinemia, an ADAMTS13 inhibitor and the production of ADAMTS13 in HSCs. The determination of ADAMTS13:AC and its substrate will give us new insights into the pathophysiology of acute alcoholic liver injury and help to elucidate additional therapeutic strategies for this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19630717     DOI: 10.2174/1874473710801020188

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  5 in total

1.  Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure.

Authors:  K S Prasanna; Ashish Goel; G Jayakumar Amirtharaj; Anup Ramachandran; K A Balasubramanian; Ian Mackie; Uday Zachariah; K G Sajith; Elwyn Elias; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2016-11-08

2.  Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hepatol       Date:  2011-07-18

Review 3.  The effect of inflammatory cytokines in alcoholic liver disease.

Authors:  Hideto Kawaratani; Tatsuhiro Tsujimoto; Akitoshi Douhara; Hiroaki Takaya; Kei Moriya; Tadashi Namisaki; Ryuichi Noguchi; Hitoshi Yoshiji; Masao Fujimoto; Hiroshi Fukui
Journal:  Mediators Inflamm       Date:  2013-12-09       Impact factor: 4.711

4.  ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability.

Authors:  Hiroaki Takaya; Tadashi Namisaki; Shohei Asada; Satoshi Iwai; Takahiro Kubo; Junya Suzuki; Masahide Enomoto; Yuki Tsuji; Yukihisa Fujinaga; Norihisa Nishimura; Yasuhiko Sawada; Kosuke Kaji; Hideto Kawaratani; Kei Moriya; Takemi Akahane; Masanori Matsumoto; Hitoshi Yoshiji
Journal:  J Clin Med       Date:  2022-03-26       Impact factor: 4.241

5.  Acute liver injury induced by low dose dimethylnitrosamine alters mediators of hepatic vascular flow.

Authors:  G Jayakumar Amirtharaj; Kavitha R Thangaraj; Archana Kini; Raghupathy V; Ashish Goel; Eapen C E; Aparna Venkatraman; Anna B Pulimood; Balasubramanian K A; Anup Ramachandran
Journal:  Toxicol Rep       Date:  2014-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.